WeightWatchers has expanded its services to include telehealth weight loss management through the WeightWatchers Clinic, accessible via the WeightWatchers app. Following its acquisition of digital health company Sequence in May, the company now offers telehealth access to certified clinicians and FDA-approved medications, with a focus on GLP-1 medications.
The GLP-1 program, designed by WeightWatchers' team of specialists, addresses the specific behavioural and nutritional needs of individuals using GLP-1 medications like Ozempic or Mounjaro. This move reflects the company's commitment to providing comprehensive support for weight loss and addressing challenges associated with new weight loss medications.
The GLP-1 program by WeightWatchers aims to fill a crucial gap in the market, recognising that behavioural modification is essential for patients successfully using GLP-1 medications and maintaining weight loss. Developed by obesity specialists, clinicians, behaviour-change scientists, dietitians, and fitness experts, the program offers specialised behavioural support, focusing on nutrition and activity. It addresses challenges unique to individuals on GLP-1 medications, such as reduced appetite, significant weight loss, and muscle loss, by helping members establish and adhere to healthy habits.
The program emphasises the importance of dietary protein, nutrient-dense foods, hydration, and movement goals to support individuals on their GLP-1 journey and minimise the impact of medication-related factors on their weight loss efforts.
Click here to read the original news story.